The STIM-ADHF Study
Primary Purpose
Acute Decompensated Heart Failure
Status
Active
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
CPNS Therapy
Sponsored by
About this trial
This is an interventional treatment trial for Acute Decompensated Heart Failure focused on measuring Neurostimulation, Contractility, Right Pulmonary Artery
Eligibility Criteria
Inclusion Criteria:
- Admitted to the hospital or planned to be admitted with a principal diagnosis of acute decompensated heart failure
- BMI adjusted BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL
- LVEF ≤ 50%
- At least one sign/symptom of fluid overload
- At least one of the following:
- Inadequate diuretic response
- At least one sign or symptom of low perfusion
Exclusion Criteria:
- Received an inotrope during current hospitalization
- Requires mechanical support
- Cardiogenic shock or impending cardiogenic shock
- Multi-organ failure
- Systolic blood pressure < 80mmHg or > 140mmHg
- Symptomatic hypotension
- eGFR < 25 mL/min/1.732
- Severe hepatic disease
Sites / Locations
- Semmelweis University, Heart and Vascular Center
- Hearth Faculty of Medicine, University of Pécs
- Szegedi Tudományegyetem ÁOK
- American Heart of Poland
- Stredoslovenský Ústav srdcových a Cievnych Chorȏb, a.s.
- CINRE s.r.o
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
CPNS Therapy
Arm Description
Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care.
Outcomes
Primary Outcome Measures
Occurrence of related adverse events
The following measures will be characterized in all enrolled subjects: occurrence of all procedure, device and therapy related adverse events, serious adverse events and deaths
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05313438
Brief Title
The STIM-ADHF Study
Official Title
Cardiac Pulmonary Nerve STIMulation in Acute Decompensated Heart Failure
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
May 10, 2022 (Actual)
Primary Completion Date
September 2023 (Anticipated)
Study Completion Date
September 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cardionomic Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The STIM-ADHF Study is a multi-center, observational study to assess the performance and safety of the CPNS System in patients with ADHF.
Detailed Description
The CPNS System is a neuromodulation system used to treat ADHF, a sudden or slow deterioration of chronic heart failure. The CPNS system is intended to provide acute (≤ 5 days) endovascular stimulation of the cardiac autonomic nerves in the right pulmonary artery (PA) in hospitalized ADHF patients. The system consists of an acute temporary neuromodulation stimulation catheter placed in the right pulmonary artery via venous access and a custom stimulator, denoiser, and associated cables. The CN2 Catheter is delivered to the right PA and provides an inotropic and/or lusitropic therapeutic effect by electrical stimulation to the terminal sympathetic nerve branches within the cardio-pulmonary plexus. The study will be conducted at up to 20 study sites worldwide. Up to 50 subjects who meet the eligibility criteria, will be enrolled, treated in-hospital with the Cardionomic CPNS System, monitored closely throughout the hospitalization and followed through 30 days post hospital discharge to evaluate the effect of the CPNS treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Decompensated Heart Failure
Keywords
Neurostimulation, Contractility, Right Pulmonary Artery
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CPNS Therapy
Arm Type
Experimental
Arm Description
Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care.
Intervention Type
Device
Intervention Name(s)
CPNS Therapy
Intervention Description
Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
Primary Outcome Measure Information:
Title
Occurrence of related adverse events
Description
The following measures will be characterized in all enrolled subjects: occurrence of all procedure, device and therapy related adverse events, serious adverse events and deaths
Time Frame
Enrolment to 30 Days post hospital discharge
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Admitted to the hospital or planned to be admitted with a principal diagnosis of acute decompensated heart failure
BMI adjusted BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL
LVEF ≤ 50%
At least one sign/symptom of fluid overload
At least one of the following:
Inadequate diuretic response
At least one sign or symptom of low perfusion
Exclusion Criteria:
Received an inotrope during current hospitalization
Requires mechanical support
Cardiogenic shock or impending cardiogenic shock
Multi-organ failure
Systolic blood pressure < 80mmHg or > 140mmHg
Symptomatic hypotension
eGFR < 25 mL/min/1.732
Severe hepatic disease
Facility Information:
Facility Name
Semmelweis University, Heart and Vascular Center
City
Budapest
Country
Hungary
Facility Name
Hearth Faculty of Medicine, University of Pécs
City
Pécs
Country
Hungary
Facility Name
Szegedi Tudományegyetem ÁOK
City
Szeged
Country
Hungary
Facility Name
American Heart of Poland
City
Bielsko Biala
Country
Poland
Facility Name
Stredoslovenský Ústav srdcových a Cievnych Chorȏb, a.s.
City
Banská Bystrica
ZIP/Postal Code
97401
Country
Slovakia
Facility Name
CINRE s.r.o
City
Bratislava
Country
Slovakia
12. IPD Sharing Statement
Learn more about this trial
The STIM-ADHF Study
We'll reach out to this number within 24 hrs